MICHAELE OOSTENDORP: Open Payments
NPI 1154329423 · RIVERVIEW, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,057 in 63 payments from 14 companies in 2025. Trend: 2023 $1,746 · 2024 $1,406 · 2025 $1,057
Food & beverage: $1,057
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 16 | $260 |
| Lilly USA, LLC | 12 | $159 |
| PFIZER INC. | 9 | $136 |
| ABBVIE INC. | 5 | $90 |
| AstraZeneca Pharmaceuticals LP | 4 | $81 |
| Astellas Pharma US Inc | 3 | $62 |
| GlaxoSmithKline, LLC. | 3 | $53 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $47 |
| Phathom Pharmaceuticals, Inc. | 2 | $44 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $36 |
Products named: Wegovy, NURTEC ODT, JARDIANCE, MOUNJARO, VRAYLAR, Veozah, Ozempic, AIRSUPRA.
Industry payments across MI — which companies pay providers there.
